22:00:04 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-24 Ordinarie utdelning 2CUREX 0.00 SEK
2024-05-23 Årsstämma 2024
2024-05-23 Kvartalsrapport 2024-Q1
2024-02-29 Extra Bolagsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-11-14 Extra Bolagsstämma 2023
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-29 Kvartalsrapport 2023-Q1
2023-05-26 Ordinarie utdelning 2CUREX 0.00 SEK
2023-05-25 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2023-02-10 Extra Bolagsstämma 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-25 Ordinarie utdelning 2CUREX 0.00 SEK
2022-05-24 Kvartalsrapport 2022-Q1
2022-05-24 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-28 Ordinarie utdelning 2CUREX 0.00 SEK
2021-05-27 Årsstämma 2021
2021-05-27 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-02 Extra Bolagsstämma 2020
2020-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2020-05-28 Kvartalsrapport 2020-Q1
2020-05-28 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-22 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2019-05-28 Årsstämma 2019
2019-05-17 Kvartalsrapport 2019-Q1
2019-04-02 Extra Bolagsstämma 2019
2019-03-01 Bokslutskommuniké 2018
2018-11-23 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2018-05-28 Årsstämma 2018
2018-05-18 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
2cureX är verksamma inom cancerbehandling. Idag tillhandahåller bolaget olika verktyg som används av läkare vid behandlingar för att mäta effekt och resistens hos cancerläkemedel på patientens egna cancerceller. Målet är att förkorta behandlingsperioden samt hitta rätt individuell behandling. Idag innehas störst verksamhet på den europeiska marknaden. Huvudkontoret ligger i Köpenhamn.
2024-02-12 14:00:00

The shareholders of 2cureX AB (publ) (“2Curex”), org. no. 559128-0077, are hereby invited to an extraordinary general meeting. The extraordinary general meeting will be held at 15:00 (CEST) on Thursday 29 February 2024 at the premises of PwC, located at Anna Lindhs Plats 4 in Malmö.

Notification of participation etc.

Shareholders who wish to attend the extraordinary general meeting must:

  • be recorded as shareholders in the share register maintained by Euroclear Sweden AB on Wednesday 21st of February 2024, and;
  • no later than Friday 23rd of February 2024 have given written notice of their participation by mail to 2cureX AB, c/o Talenom Consulting AB, Lilla Strandgatan, 261 22 Landskrona. Notice can also be done by email to ir@2curex.com. The notification should state name, personal identification number or registration number, address, daytime phone number and when applicable information regarding any representative, proxy and or at most two assistants. If applicable, the notification must include authorization documents such as a certificate of registration or equivalent documents.

Nominee-registered shares

A shareholder who has its shares registered with a nominee must, to be entitled to participate in the extraordinary general meeting, have the shares registered in its own name through the nominee, so that the shareholder is registered in the share register kept by Euroclear Sweden AB on the record date of Wednesday 21st of February 2024. Such registration may be temporary (so-called voting rights registration). Shareholders who wish to register the shares in their own name must, in accordance with the respective nominee's routines, request that the nominee make such voting rights registration. Registration of voting rights that have been requested by shareholders at such a time that the registration has been made by the relevant nominee no later than Friday 23rd of February 2024 will be taken into account in the production of the share register.

Proxy

Shareholders represented by proxy shall issue a written and dated power of attorney signed by the shareholder. A power of attorney issued by a legal entity shall have a registration certificate attached, or if such certificate does not exist, equivalent documents. The original power of attorney and any registration certificate should, in advance of the extraordinary general meeting, be sent to the company at the address above.

Proposed agenda

  1. Appointment of a Chairman of the extraordinary general meeting
  2. Preparation and approval of the voting register
  3. Approval of the agenda
  4. Appointment of one (1) or two (2) persons to verify the minutes of the meeting
  5. Determination of whether the extraordinary general meeting was duly convened
  6. Election of a new board member
  7. Closure of the extraordinary general meeting

Election of a new board member directors (item 6)

Shareholders in the company propose that the extraordinary general meeting elect a new member of the Board of Directors. The suggested new board member will be presented at a later stage or at the extraordinary general meeting.

The Board of Directors hereafter consists of Tonny Bülow-Nielsen, Ole Thastrup and the newly elected member.

Other

The notice and proxy forms will be made available at the premises of the company, 2cureX, Fruebjergvej 3, 2100 Copenhagen, Denmark and on the company’s website (www.2curex.com) and will be sent to the shareholders who request it and state their postal address.

Shareholders are informed of their right under Chapter 7, Section 32 of the Swedish Companies Act to request information from the Board of directors and the CEO.

___________

Malmö in February 2024

2cureX AB (publ)

The Board of Directors

N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the extraordinary general meeting in 2cureX AB, and in case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.